Patents by Inventor Rheal A. Towner
Rheal A. Towner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11660280Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.Type: GrantFiled: September 10, 2018Date of Patent: May 30, 2023Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventor: Rheal A. Towner
-
Publication number: 20220354815Abstract: The present invention includes compositions and methods for treating a proliferative disease in a patient that comprises administering to the patient a therapeutically effective amount of 2,4-Disulfonyl-N-Tert-Butylnitrone, 2,4-disulfonyl ?-phenyl tertiary butyl nitron or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 19, 2020Publication date: November 10, 2022Inventor: Rheal A. Towner
-
Publication number: 20220195024Abstract: The present disclosure is directed to novel monoclonal antibodies that bind to ELTD 1 and methods for use thereof, including, detection and treatment of cancer, multiple sclerosis, retinopathy, or promoting tissue regeneration.Type: ApplicationFiled: November 1, 2019Publication date: June 23, 2022Inventors: Rheal A. Towner, Junho Chung
-
Publication number: 20210069354Abstract: Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of a therapeutic and/or diagnostic agent, along with an amount of 2,4-disulfonyl a-phenyl tertiary butyl nitrone (2,4-DSPBN), said therapeutic and/or diagnostic agent being characterized as being unable or poorly able, in the absence of said amount of 2,4-DSPBN, to cross the blood-brain barrier or the blood-cochlear barrier or the blood-cerebrospinal fluid barrier of said subject.Type: ApplicationFiled: November 18, 2020Publication date: March 11, 2021Inventors: Richard D. Kopke, Rheal A. Towner
-
Publication number: 20200215015Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.Type: ApplicationFiled: September 10, 2018Publication date: July 9, 2020Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventor: Rheal A. TOWNER
-
Patent number: 10398659Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: GrantFiled: April 12, 2018Date of Patent: September 3, 2019Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal A. Towner, Robert A. Floyd
-
Patent number: 10111843Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: GrantFiled: June 23, 2017Date of Patent: October 30, 2018Assignees: Hough Ear Institute, Oklahoma Medical Research FoundationInventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
-
Publication number: 20180256756Abstract: Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of a therapeutic and/or diagnostic agent, along with an amount of 2,4-disulfonyl a-phenyl tertiary butyl nitrone (2,4-DSPBN), said therapeutic and/or diagnostic agent being characterized as being unable or poorly able, in the absence of said amount of 2,4-DSPBN, to cross the blood-brain barrier or the blood-cochlear barrier or the blood-cerebrospinal fluid barrier of said subject.Type: ApplicationFiled: September 14, 2016Publication date: September 13, 2018Applicants: Oklahoma Medical Research Foundation, Hough Ear InstituteInventors: Richard D. KOPKE, Rheal A. TOWNER
-
Publication number: 20180228744Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: ApplicationFiled: April 12, 2018Publication date: August 16, 2018Inventors: Rheal A. TOWNER, Robert A. FLOYD
-
Patent number: 10030076Abstract: The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.Type: GrantFiled: January 6, 2015Date of Patent: July 24, 2018Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal Towner, Jonathan Wren
-
Patent number: 10022346Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: GrantFiled: January 27, 2017Date of Patent: July 17, 2018Assignees: Hough Ear Institute, Oklahoma Medical Research FoundationInventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
-
Patent number: 9968569Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: GrantFiled: October 13, 2016Date of Patent: May 15, 2018Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal A. Towner, Robert A. Floyd
-
Publication number: 20170281583Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: ApplicationFiled: June 23, 2017Publication date: October 5, 2017Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
-
Publication number: 20170202797Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: ApplicationFiled: January 27, 2017Publication date: July 20, 2017Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
-
Patent number: 9642823Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: GrantFiled: February 18, 2016Date of Patent: May 9, 2017Assignees: Hough Ear Institute, Oklahoma Medical Research FoundationInventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
-
Publication number: 20170027891Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: ApplicationFiled: October 13, 2016Publication date: February 2, 2017Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal A. TOWNER, Robert A. FLOYD
-
Publication number: 20170008969Abstract: The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.Type: ApplicationFiled: January 6, 2015Publication date: January 12, 2017Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal TOWNER, Jonathan WREN
-
Patent number: 9474748Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: GrantFiled: January 21, 2014Date of Patent: October 25, 2016Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal A. Towner, Robert A. Floyd
-
Publication number: 20160158173Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: ApplicationFiled: February 18, 2016Publication date: June 9, 2016Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
-
Patent number: 9289404Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: GrantFiled: February 3, 2012Date of Patent: March 22, 2016Assignees: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner